ZED 1227

Drug Profile

ZED 1227

Alternative Names: ZED-101; ZED1227

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zedira GmbH
  • Developer Dr Falk Pharma; University Medical Center of the Johannes Gutenberg University Mainz; Zedira GmbH
  • Class Small molecules
  • Mechanism of Action Transglutaminase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease

Most Recent Events

  • 19 Jul 2018 Chemical structure information added
  • 02 Jun 2018 Efficacy data from a preclinical studies in Coeliac disease presented at the at Digestive Disease Week 2018 (DDW-2018)
  • 11 May 2018 ZED 1227 is still in phase I trials for Coeliac disease (In volunteers) in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top